These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 18370448)

  • 41. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials.
    Papakostas GI; Montgomery SA; Thase ME; Katz JR; Krishen A; Tucker VL
    J Clin Psychiatry; 2007 Dec; 68(12):1907-12. PubMed ID: 18162022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.
    DeBattista C; Solvason HB; Poirier J; Kendrick E; Schatzberg AF
    J Clin Psychopharmacol; 2003 Feb; 23(1):27-30. PubMed ID: 12544372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.
    Papakostas GI; Trivedi MH; Alpert JE; Seifert CA; Krishen A; Goodale EP; Tucker VL
    J Psychiatr Res; 2008 Jan; 42(2):134-40. PubMed ID: 17631898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
    Clayton AH; McGarvey EL; Abouesh AI; Pinkerton RC
    J Clin Psychiatry; 2001 Mar; 62(3):185-90. PubMed ID: 11305705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.
    DeBattista C; Solvason B; Poirier J; Kendrick E; Loraas E
    J Clin Psychiatry; 2005 Jul; 66(7):844-8. PubMed ID: 16013899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Escitalopram versus venlafaxine XR in the treatment of depression.
    Montgomery SA; Andersen HF
    Int Clin Psychopharmacol; 2006 Sep; 21(5):297-309. PubMed ID: 16877901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder.
    Bradley RH; Barkin RL; Jerome J; DeYoung K; Dodge CW
    Am J Ther; 2003; 10(5):318-23. PubMed ID: 12975715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.
    Shen Y; Zhao Q; Yu Y; Tan Y; Zhang H; Xu X; Wang Z; Li Y; Hu J; Zhong J; Li H
    J Affect Disord; 2019 Oct; 257():143-149. PubMed ID: 31301615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
    Safarinejad MR
    BJU Int; 2010 Sep; 106(6):840-7. PubMed ID: 20067456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
    Brignone M; Diamand F; Painchault C; Takyar S
    Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.